TREAT CTC

BIG 1-12

Partager cette publication

TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC)

Contenu de va-et-vient

This study is coordinated and sponsored by the EORTC, in collaboration with BCG, SUCCESS, UNICANCER and under the umbrella of the Breast International Group.

Pharmaceutical partners: Roche, Janssen Diagnostics

This study is funded by an educational grant from Roche and run under BIG’s Principles of Research Conduct.

NCT01548677

More To Explore

PANACEA

Panacea BIG 4-13 PANACEA stands for anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer. A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab

Read More

DECRESCENDO

DECRESCENDO BIG 19-02 De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Share

Read More